Progress 01/01/12 to 09/30/14
Outputs
Target Audience: Target audience includes beef producers, veterinarians, and research scientists. Changes/Problems:
Nothing Reported
What opportunities for training and professional development has the project provided? One Master's level graduate student was trained in animal husbandry, bench level research, the scientific method, animal biosafety level three and biosafety level three biocontainment research resulting in completion of a masters thesis and masters degree. How have the results been disseminated to communities of interest? Preliminary results have been disseminated at local scientific presenations for scientists and at local brucellosis meetings which included legislators and cattle producers. Additional lay-articles will be prepared on the results of this study for local Wyoming periodicals. A master's thesis has been generated based on this project and will be final published by May 2015. One or two peer-reviewed journal articles will be published in 2015. What do you plan to do during the next reporting period to accomplish the goals?
Nothing Reported
Impacts
What was accomplished under these goals?
1. Collection of controlled experimental data in our study strongly suggest there are no negativeeffects of RB51 boosts on pregnant cattle.These dataprovide a scientific basis for the inclusionof pregnant cattlein future vaccine regimens. In addition, the data collected during our study will serve as preliminary data for a larger clinical-type study on this phenomenon.Our resultsprovide powerful incentives to both producers and veterinarians to modify RB51 vaccine practices from a single calfhood vaccine to multiple annual vaccine boosts. The increse in RB51 vaccine doses resulted in increased protection from both Brucella infection and Brucella-induced abortions saving money, reducing cattle to cattle, cattle to wildlife and potentially cattle to human Brucella transmission. 2. Our results were less compelling for the use of new bovine-specific T-cell assays as our data was not equivocal. However, we were able to demonstrate an increase in CMI following multi-dose RB51 vaccination. 3. Understanding the utility and risks of boosting cattle with RB-51 vaccine may lead to a more better rationale for vaccine policy for the state of Wyoming, reduce disease incidence in an economically important food source and help reduce/break the cycle of brucellosis transmission from infected wildlife such as elk. We expect thatour compellingdata will help producers and veterinarians make more rational, cost-effective decisions on if/when to vaccinate at-risk cattle both within and outside the designated surveillance area and other areas in the world were B. abortus infection is present. We were able to demonstrate significantly decreased infection and bacterial load in multi-dose vaccinated cattle indicating a likely reduction in horizontal disease transmission risk. And for the first time we were also able to demonstrate a complete lack of infection in calfs of multi-dose infected cattle indicating that we were able to block vertical transmission of brucellosis.
Publications
- Type:
Theses/Dissertations
Status:
Awaiting Publication
Year Published:
2015
Citation:
Kesterson, Alexandria.E. Evaluation of the Role of Cell-Mediated Immunity and Efficacy of Experimental Alternative Schedule of Live Attenuated RB51 Vaccine against Brucellosis in Cattle, MS, Department of Veterinary Science, University of Wyoming
- Type:
Journal Articles
Status:
Awaiting Publication
Year Published:
2015
Citation:
Efficacy of Experimental Alternative Schedule of Live Attenuated RB51 Vaccine against Brucellosis in Cattle
|
Progress 12/28/12 to 09/30/13
Outputs
Target Audience: Cattle ranchers, clinical veternarians Changes/Problems:
Nothing Reported
What opportunities for training and professional development has the project provided? This project has provided training opportunites for two undergraduate and two graduate students in bovine husbandry, veterinary care and treament, vaccination, artificial insemination, research methods development and application of the scientific method. How have the results been disseminated to communities of interest? During this reporting period the results have been disseminated to the Wyoming livestock board via presentation. We also provided a scienfic presentation to the Brucellosis Coordination team. What do you plan to do during the next reporting period to accomplish the goals? During the next reporting period we project to complete all our planned studies on the immunological response to multiple RB-51 vaccinations. In addition, we have expanded the study with other resources to include a field strain (virulent) brucellosis challenge of pregnant cattle given 0/1/2/or 3 doses of RB-51 vaccine. These additional studies will strengthen the relavance of the proposed studies and increase their relevance to the scientific community, veternarians, cattle producers and the USDA.
Impacts
What was accomplished under these goals?
2nd dose of vaccine administered. Cell methodologies to assess proliferation to RB51 developed. New bovine macrophage cell line developed and tested. Study expanded to include field strain brucellosis challenge of vaccinated cattle (June 2014).
Publications
|
Progress 01/01/12 to 12/27/12
Outputs
OUTPUTS: No discernable outputs have been achieved as the study has not reached a definitive milestone as of December 2012. PARTICIPANTS: Dr. Jeff Adamovicz, Ph.D., RBP, lead investigator; Dr. Brant Schumaker DVM; Dr. Walt Cook DVM; Dr. Scott Lake DVM; artifical insemination Ms. Alex Kesterson, MS candidate; Dr. Steve Olsen, Ph.D. ARS, USDA Collaborator for challenge studies TARGET AUDIENCES: Clinical veterinarians, ranchers, beef producers, wildlife managers PROJECT MODIFICATIONS: We have arranged to have our pregnant cattle challenged with virulent Brucella abortus in the ARS, USDA ABSL-3 facility in Ames, Iowa. This goal was not part of our original proposal but will significantly improve the relevance of our data and conclusions. This effort is separately funded.
Impacts
Our proposed cattle vaccinations are underway. We have written and received approval for our experimental animal use cattle protocol. We have bred and delivered 25 healthy calves. We have administered the first dose of RB-51 vaccine to these cattle along with other standard veterinary care. We have collected and stored white blood cells from these cattle per our experimental protocol. During this past year we have developed methodologies to measure cell mediated immunity in cattle. This development effort will allow us to achieve our specific aim two. In addition, the use of these methods will support future research on Brucellosis in cattle. Our research is proceeding per our proposal and our staff has procured straws to inseminate our test cattle.
Publications
- No publications reported this period
|
|